Compare COHR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHR | REGN |
|---|---|---|
| Founded | 1971 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7B | 68.6B |
| IPO Year | 1995 | 1995 |
| Metric | COHR | REGN |
|---|---|---|
| Price | $279.24 | $673.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | $264.62 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 4.4M | 908.6K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ 71.74 | 8.19 |
| EPS | 2.92 | ★ 6.75 |
| Revenue | $1,158,794,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $21.72 | $12.45 |
| Revenue Next Year | $24.63 | $10.13 |
| P/E Ratio | ★ $94.40 | $100.41 |
| Revenue Growth | 19.21 | ★ 20.82 |
| 52 Week Low | $84.35 | $541.00 |
| 52 Week High | $440.00 | $821.11 |
| Indicator | COHR | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 60.87 |
| Support Level | $220.10 | $668.85 |
| Resistance Level | $290.68 | $783.87 |
| Average True Range (ATR) | 25.27 | 15.32 |
| MACD | -8.44 | 4.42 |
| Stochastic Oscillator | 16.02 | 75.99 |
Coherent Corp is a vertically integrated manufacturing company that develops, manufactures, and markets lasers, transceivers, and other optical and optoelectronic devices, modules, and systems, as well as engineered materials, for use in the communications, industrial, instrumentation, and electronics markets. Its reporting segments are Datacenter Communications and Industrial. Its geographic areas are North America, Europe, China, Japan, and the rest of the world.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.